New Alzheimer’s treatment ‘lecanemab’ approved for use in the US
LifeArc played an instrumental role in the drug’s development through our antibody humanisation work.
LifeArc and DEBRA Austria launch £2.5m funding call for repurposing therapies for Epidermolysis Bullosa
Joint initiative part of LifeArc’s £100 million Translational Challenge to help address rare disease translational science.
New UK-based research project brings together world-leading institutions to transform care for people living with dementia
Brings together the world-leading expertise of Health Data Research UK, University of Edinburgh, LifeArc, Eisai and Gates Ventures
LifeArc strengthens Board of Trustees with new appointments
Dr Terri Cooper, Dr Sameer Mistry and Dr Rima Makarem join LifeArc's Board of Trustees as Non-Executive Directors.
New programme to move potential MND drugs into clinical trials faster
EXPERTS-ALS to screen candidate drugs at scale and identify those that should be fast-tracked to larger clinical trials
LifeArc and Sarcoma UK fund research to guide treatment decisions in rare cancer
£150,000 grant will fund a study of a biomarker test that could improve outcomes for patients with a rare sarcoma cancer.
LifeArc announces strategic partnership with PrecisionLife as part of its Motor Neuron Disease Translational Challenge
LifeArc and PrecisionLife will work together to select and validate multiple novel targets and their accompanying patient stratification biomarkers.
Meet our industrial placement students – class of 2023
Find out what this year's cohort of industrial placement students gained from the experience.
LifeArc & Cystic Fibrosis Trust announce new £15m research funding to fast track treatment of lung infections
Focussing on innovative approaches to improve quality of life for people with cystic fibrosis (CF)